Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Carcinoma, Small Cell × ARQ 197 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 3 Carcinoma, Renal Cell 2 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solitary Fibrous Tumor, Pleural 1 Seminoma 1 Sarcoma, Clear Cell 1 Sarcoma, Alveolar Soft Part 1 Renal Insufficiency 1 Paraproteinemias 1 Pancreatic Neoplasms 1 Osteolysis 1 Multiple Myeloma 1 Mesothelioma, Malignant 1 Hypercalcemia 1 Hematologic Neoplasms 1 Fractures, Spontaneous 1 Colorectal Cancer Metastatic 1 Carcinoma, Small Cell 1 Carcinoma 1 Breast Neoplasms 1 Bone Diseases, Metabolic 1 Anemia 1 Amyloidosis 1

Interventions

Pemetrexed 3 Gemcitabine 3 Topotecan 2 Carboplatin 2 vosaroxin 1 vinflunine 1 taxane 1 lurtotecan 1 liposomal doxorubicin 1 enzalutamide 1 bemiparin 1 apalutamide 1 abiraterone 1 Vinorelbine 1 RRx-001 1 Paclitaxel 1 Nivolumab 1 Irinotecan 1 Ipilimumab 1 Etoposide 1 Docetaxel 1 Cisplatin 1 BI 2536 1 Arsenic Trioxide 1 ARQ 197 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02608411 2023-10-13

TIMES

Istituto Oncologico Veneto IRCCS

Phase 2 Terminated

Carcinoma, Small Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡